bearish

Resapp Health

ResApp’s Revised Offer from Pfizer Still Faces Headcount Test Risk

The risk/reward profile is unfavourable as ResApp is a highly-held retail stock, posing a headcount test risk to the scheme. At the last close, the gross spread is 9.5%.

Event-Driven
233 Views, 04 Aug 2022 15:18
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top 5%
Arun George
IPOs and Catalysts/Events
Global Equity Research Ltd
Information TechnologyEquitiesEquity Capital MarketsEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • Merger Arb Mondays (15 Aug) - Lifestyle Intl, EVOC, Giordano, Yashili, Alliance Aviation, ResApp
    15 Aug 2022
  • Merger Arb Mondays (08 Aug) - Yashili, Lifestyle, Link, Infomedia, Ramsay, ResApp, Alliance Aviation
    08 Aug 2022
  • Weekly Deals Digest (07 Aug) - Hongjiu Fruit, Link, Infomedia, Atlas Arteria, ResApp, DTAC/True
    07 Aug 2022
  • ResApp’s Revised Offer from Pfizer Still Faces Headcount Test Risk
    04 Aug 2022
  • ResApp’s Confirmatory Study Fails, Resulting in Pfizer’s Lower A$0.146 Offer
    21 Jun 2022
  • ResApp Draws a Revised Binding Offer from Pfizer
    14 Jun 2022
x